Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock. 
Via The Motley Fool
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products. 
Via Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in patients with opioid use disorder. Findings highlight the need for more research... 
Via Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose. 
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
Via Benzinga
In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Looking Into Eli Lilly's Recent Short Interest
Via Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to... 
Via Benzinga
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and... 
Via Benzinga
Exposures Product Safety
Why This Stock Could Be the Nvidia of Healthcare
The opportunities for artificial intelligence (AI) to have an impact in the healthcare space are enormous. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now? 
Via MarketBeat
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
Eli Lilly's Kisunla (donanemab) has been approved in Japan for early symptomatic Alzheimer's, including mild cognitive impairment and dementia stages. The approval is based on data showing Kisunla... 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
History shows that Eli Lilly tends to do something special with its stock toward the end of the year. 
Via The Motley Fool
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
NFLX is among four stocks on the list that's actionable now. 
Via Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout. 
Via The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules
Eli Lilly appeals a $183 million judgment in a Medicaid fraud case, arguing that it followed a reasonable interpretation of the law. The case has drawn attention from major business and pharmaceutical... 
Via Benzinga
Topics Fraud
Exposures Legal
Why Tandem Diabetes Care Stock Thrashed the Market Today
At a stroke, it's got a product authorized for a specific use in 27 countries. 
Via The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
Eli Lilly stock may look expensive, but that may not be the case in a few years as the business grows at a rapid pace. 
Via The Motley Fool
Prediction: This Will be Eli Lilly's Next Big Move.
Lilly could take a step that's positive for the stock and investors over the long term. 
Via The Motley Fool
Why ResMed Stock Tumbled by 5% Today
A looming threat from a very powerful rival could significantly dampen a key business for the company. 
Via The Motley Fool
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive. 
Via The Motley Fool
ADX: A High-Yielding, Diversified CEF Worth Looking Into
When it comes to investing, there are two critical “bedrocks” we need to keep in mind. These two facts are why 95% of my favorite high-income investments, closed-end funds (CEFs), have made investors... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.